Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-23T02:13:35.710Z Has data issue: false hasContentIssue false
  • English
  • Français

Investigation of alpha-synuclein in patients with late-onset schizophrenia

Published online by Cambridge University Press:  01 September 2022

E. Palchikova ,
M. Nikolaev ,
A. Lavrinova ,
N. Neznanov ,
S. Pchelina  and
N. Zalutskaya
E. Palchikova*
Affiliation:
V.M.Bekhterev National Medical Research Center for Psychiatry and Neurology, Geriatric Psychiatry, St.Peterburg, Russian Federation
M. Nikolaev
Affiliation:
Saint Petersburg Nuclear Physics Institute Named by B.P. Konstantinovof National Research Centre“Kurchatov Institute”, Molecular Biology, Saint Petersburg, Russian Federation
A. Lavrinova
Affiliation:
Saint Petersburg Nuclear Physics Institute Named by B.P. Konstantinovof National Research Centre“Kurchatov Institute”, Molecular Biology, Saint Petersburg, Russian Federation
N. Neznanov
Affiliation:
Bekhterev National Medical Center for Psychiatry and Neurology, Geriatric Psychiatry, Saint-Petersburg, Russian Federation
S. Pchelina
Affiliation:
Saint Petersburg Nuclear Physics Institute Named by B.P. Konstantinovof National Research Centre“Kurchatov Institute”, Molecular Biology, Saint Petersburg, Russian Federation
N. Zalutskaya
Affiliation:
V.M.Bekhterev National Medical Research Center for Psychiatry and Neurology, Geriatric Psychiatry, St.Peterburg, Russian Federation
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

There is no consensus about whether late-onset schizophrenia(LOS) is a type of schizophrenia or a secondary psychotic disorder. One of the theories of the occurrence of late-onset psychoses is neurodegeneration caused by the imbalance of proteostasis.

Objectives

To study the concentration and expression of alpha-synuclein in patients with LOS compared with controls.

Methods

The study involved 42 patients with the ICD-10 criteria of schizophrenia with the onset of the disease after 45 years and 104 controls with no dementia and severe somatic pathology, comparable in age and gender. The alpha-synuclein level was estimated in a lymphocytic cell fraction from patients with LOS N=42 and controls N=104 using the Human alpha-synuclein ELISA kit. The expression of the SNCA gene was studied in 22 LOS patients and 22 controls and determined by PCR using the SYBR Green Supermix kit and the CFX96 instrument in comparison with the referent genes using previously developed primers. LOS group underwent psychopathological examination including scales. Statistics: SPSS 12.0; the Mann–Whitney test; exponential regression analysis; data is given as median (min–max). The level of significance was set at p<0.05.

Results

The alpha-synuclein level is higher in patients with LOS (9.21 (0.78-29.52)) compared to control (6,355 (0.46-35.44)), p=0.024. The mRNA level of the SNCA gene is higher in the LOS group (0.533 (0.089-1.406)) compared to controls (0.087 (0.016-0.266) , p<0.001.

Conclusions

Our study shows the relationship of alpha-synuclein with the manifestations of LOS. Obtained novel data can open up new targets for therapy and bring it closer to understanding the phenomenon.

Disclosure

No significant relationships.

Keywords

schizophréniaproteostasisalpha-synucleinlate-onset psychosis
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S317 - S318
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.